HKTDC programme supports overseas start-ups' Asian market entry
Briefly

HKTDC programme supports overseas start-ups' Asian market entry
"For many of the selected companies, early expansion plans are focused on access to Asian and Greater Bay Area markets. Hong Kong has been cited as an operational base, thanks to regulatory frameworks, capital market access and proximity to the Chinese mainland. Several firms in the 2025 cohort have cited the city's regulatory environment, capital markets and proximity to the Chinese mainland as practical considerations when planning early Asian operations."
"Several firms in the 2025 cohort have cited the city's regulatory environment, capital markets and proximity to the Chinese mainland as practical considerations when planning early Asian operations. Health tech companies account for a substantial share of this year's cohort. Founded in 2024, UK-based abYcloud is developing an AI-driven platform for anti-body drug discovery that combines computational design with automated laboratory validation. The company reports that its system shortens development timelines compared with conventional approaches, with commercial pilots already conducted in Europe."
Many selected companies focus early expansion on access to Asian and Greater Bay Area markets, with Hong Kong used as an operational base because of regulatory frameworks, capital market access and proximity to the Chinese mainland. Health technology companies constitute a substantial portion of the cohort. UK-based abYcloud is developing an AI-driven antibody drug-discovery platform that combines computational design with automated laboratory validation, shortens development timelines and has conducted commercial pilots in Europe while targeting Asia Pacific pharmaceutical customers. Denmark's Stimuliver develops stem cell-derived liver implants using subcutaneous implantation for detoxification and hepatic functions and has established a Hong Kong entity for early clinical markets. Mainland TAO Medi-Tech specialises in additive manufacturing for personalised orthopaedic implants and surgical tools and has completed Series A financing.
Read at South China Morning Post
Unable to calculate read time
[
|
]